马飞，1976年生，籍贯江苏盐城，肿瘤内科学家，中国医学科学院肿瘤医院主任医师，博士生导师，教育部国家级重大人才项目入选者。1994年考入中国协和医科大学（现北京协和医学院）临床医学（八年制）专业，2002年获得临床医学博士学位。2002年进入中国医学科学院肿瘤医院工作，从事实体肿瘤药物治疗的临床与研究工作，2016年任主任医师。

长期致力于乳腺癌等实体瘤的基础、临床及转化研究。在肿瘤创新药物临床与转化研究、肿瘤转移与耐药机制研究、液体活检与精准诊疗研究、肿瘤大数据研究等领域开展了系列工作。

全国十大赌博官网

1. Yuanyuan Zhang#, Hongyan Chen#, Hongnan Mo#, Xueda Hu#, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu*, Fei Ma*, Zemin Zhang*, Zhihua Liu*. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021, 39(12):1578-1593 (IF=38.585)

2. Zongbi Yi#, Fei Ma*, Guohua Rong, Binliang Liu, Yanfang Guan, Jin Li, Xiaoying Sun, Wenna Wang, Xiuwen Guan, Hongnan Mo, Jiani Wang, Haili Qian, Binghe Xu*. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021, 6(1):251. (IF=38.104)

3. Binghe Xu#*, Min Yan#, Fei Ma#, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou, PHOEBE Investigators. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021, 22(3):351-360. (IF=54.433)

4. Hui Li#, Jinsong Wang, Zongbi Yi, Chunxiao Li, Haijuan Wang, Jingyao Zhang, Ting Wang, Peng Nan, Feng Lin, Dongkui Xu, Haili Qian*, Fei Ma*. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. Eur J Cancer. 2021, 145:92-108. (IF=10.002).

5. Hui-Yao Huang#, Da-Wei Wu#, Fei Ma#, Zhi-Lei Liu, Ju-Fang Shi, Xia Chen, Shu-Hang Wang, Hong Fang, Ying Bai, Yue Yu, Yuan Fang, Chao Sun, Qi Fan, Ying Wu, Rui-Hua Fan, Cai-Yun Zhou, Bao-Xia He, Min Dai, Ning Li*, Bing-He Xu, Yan Sun, Jie He. Availability of anticancer biosimilars in 40 countries. Lancet Oncol. 2020, 21(2):197-201. (IF=41.316)

6. Jian Liu #, Chunxiao Li #, Jinsong Wang #, Dongkui Xu#, Haijuan Wang, Ting Wang, Lina Li, Hui Li, Peng Nan, Jingyao Zhang, Yang Wang, Changzhi Huang, Dong Chen, Yi Zhang, Tao Wen*, Qimin Zhan*, Fei Ma*, Haili Qian*. Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. Nat Commun. 2020 Sep 8;11(1):4455. (IF=14.919).

7. Fei Ma#*, Yanfang Guan#, Zongbi Yi#, Lianpeng Chang#, Qiao Li, Shanshan Chen, Wenjie Zhu, Xiuwen Guan, Chunxiao Li, Haili Qian, Xuefeng Xia, Ling Yang, Jianjun Zhang, Hatim Husain, Zhongxing Liao, Andrew Futreal, Jian Huang, Xin Yi*, Binghe Xu*. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020, 146(5):1359-1368. (IF=7.316)

8. Fei Ma#, Quchang Ouyang#, Wei Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li, Shiying Yu, Jifeng Feng, Shusen Wang, Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu*. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. J Clin Oncol. 2019, 37(29):2610-2619. (IF=32.956)

9. Qiao Li#, Xiuwen Guan#, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma*, Binghe Xu*. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clin Cancer Res. 2019, 25(17):5212-5220. (IF=10.107)

10. Fei Ma#, Qiao Li#, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu*. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. 2017, J Clin Oncol. 35(27):3105-3112. (IF=26.303).